Fujian Medical University Union Hospital
🇨🇳China
Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC
Phase 2
- Conditions
- Small-cell Lung Cancer
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Fujian Medical University Union Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT06816966
- Locations
- 🇨🇳
Fujian Medical University Union Hospital,, Fuzhou, Fujian, China
A Prospective Multicenter Registry Study on BASIS Technique for Endovascular Therapy of Acute Large Vessel Occlusion Strokes Due to Intracranial Atherosclerotic Disease
Recruiting
- Conditions
- Acute Ischemic StrokeICAS - Intracranial Atherosclerosis
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Fujian Medical University Union Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT06881420
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Investigation on the Status Quo of Hyperalgesia in Patients After Thoracoscopic Operation and Study on the Effect of Intraoperative Intervention
Not Applicable
Recruiting
- Conditions
- Thoracoscopic SurgeryHyperalgesia
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Fujian Medical University Union Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT06790914
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fujian, Fuzhou, China
A Study of RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum
Phase 2
Recruiting
- Conditions
- Paget Disease, ExtramammaryScrotum Disease
- Interventions
- Drug: Disitamab Vedotin combined with Toripalimab
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Fujian Medical University Union Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06791070
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study
Phase 4
Not yet recruiting
- Conditions
- ALK-positive Advanced NSCLCALK-positive Non-small Cell Lung Cancer (NSCLC)MPRNeoadjuvant Therapy
- Interventions
- First Posted Date
- 2025-01-21
- Last Posted Date
- 2025-01-21
- Lead Sponsor
- Fujian Medical University Union Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06785584
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Tumor Regression Grade As Predictor of Adjuvant Therapy
Recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
- Interventions
- Drug: Chemotherapy
- First Posted Date
- 2024-11-28
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Fujian Medical University Union Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT06710665
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Insomnia with Subjective Cognitive Decline
Not Applicable
Not yet recruiting
- Conditions
- Insomnia ChronicSubjective Cognitive Decline (SCD)
- First Posted Date
- 2024-11-28
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Fujian Medical University Union Hospital
- Target Recruit Count
- 66
- Registration Number
- NCT06710652
Efficacy, Safety of Astragalus Membranaceus in Mild-to-Moderate Alzheimer's Disease
Phase 2
Completed
- Conditions
- Alzheimer Disease
- Interventions
- Drug: Astragalus Membranaceus Root
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Fujian Medical University Union Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT06694597
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Melasma
Not Applicable
Recruiting
- Conditions
- Melasma
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Fujian Medical University Union Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06677931
- Locations
- 🇨🇳
Affiliated Union Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳Chenxiaosong, Fujian, fuzhou, China
A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.
Phase 2
Not yet recruiting
- Conditions
- NMIBC
- Interventions
- Drug: Distitamab Vedotin in combination with Tislelizumab
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Fujian Medical University Union Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06630871
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
© Copyright 2025. All Rights Reserved by MedPath